Marshall Urist Biography and Net Worth

Dr. Urist Joined Royalty Pharma in 2013. Previously, Dr. Urist was an executive director and the senior biotechnology analyst at Morgan Stanley. Dr. Urist has a BA, Phi Beta Kappa, from Johns Hopkins University, a PhD from Columbia University, and an MD from Columbia University.

What is Marshall Urist's net worth?: The estimated net worth of Marshall Urist is at least $1.28 million as of February 22nd, 2023. Dr. Urist owns 46,667 shares of Royalty Pharma stock worth more than $1,281,476 as of April 16th. This net worth approximation does not reflect any other assets that Dr. Urist may own. Learn More about Marshall Urist's net worth.
How do I contact Marshall Urist?: The corporate mailing address for Dr. Urist and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on Marshall Urist's contact information.
Has Marshall Urist been buying or selling shares of Royalty Pharma?: Marshall Urist has not been actively trading shares of Royalty Pharma within the last three months. Most recently, Marshall Urist sold 23,333 shares of the business's stock in a transaction on Wednesday, February 22nd. The shares were sold at an average price of $37.30, for a transaction totalling $870,320.90. Following the completion of the sale, the executive vice president now directly owns 46,667 shares of the company's stock, valued at $1,740,679.10. Learn More on Marshall Urist's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (CEO), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, Royalty Pharma insiders bought shares 4 times. They purchased a total of 485,388 shares worth more than $15,543,025.16. In the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 2,250,753 shares worth more than $72,415,950.97. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.7% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 1/4/2024.

Marshall Urist Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/22/2023	Sell	23,333	$37.30	$870,320.90	46,667
6/24/2022	Sell	23,333	$43.19	$1,007,752.27	23,334
5/16/2022	Sell	23,333	$39.85	$929,820.05	46,667
6/7/2021	Sell	16,568	$47.02	$779,027.36	16,568
6/4/2021	Sell	16,566	$45.13	$747,623.58	16,568
6/2/2021	Sell	14,566	$41.52	$604,780.32

Marshall Urist Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $27.46

$27.46

$28.09

50 Day Range

MA: $29.90

$28.22

$31.33

2 Week Range

Now: $27.46

$25.92

$36.67

Volume

2,171,529 shs

Average Volume

2,672,410 shs

Market Capitalization

$16.41 billion

P/E Ratio

14.53

Dividend Yield

2.98%

Beta

0.45

Options trading has suddenly become more reliable.

From Eagle Publishing | Ad

When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.

Click here to see how simple option trades win 96% of the time.